Document 1036
 DOCN  M94A1036
 TI    Treatment with medroxy-progesteron-acetate reverses weight loss but not
       body cell mass depletion: results of body-impedance analysis.
 DT    9412
 AU    Stute A; Poppinger J; Spitz S; Jaegel Guedes E; Jaeger H; KIS,
       Curatorium for Immunodeficiency, Munich, Germany.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(2):223 (abstract no. PB0907). Unique
       Identifier : AIDSLINE ICA10/94371539
 AB    INTRODUCTION: Cachexia is a common complication in HIV disease. Therapy
       with anabolic steroids like medroxy progesteron acetate (MPA) increases
       the appetite and food intake. It is unclear, how the body composition is
       influenced by MPA treatment. OBJECTIVE: To analyze efficacy and
       tolerance of medroxy progesteron Acetate (MPA) therapy in cachectic HIV
       patients. METHODS: Retrospective analysis of patients who were treated
       with MPA (1000 mg qd). From January 1st 1992 to December 31st 1993, 31
       Patients were treated MPA. The mean treatment duration was 11 weeks. A
       body impedance analysis was performed on all patients before and after
       treatment. TOLERANCE AND ADVERSE REACTIONS: The tolerance of MPA was
       good. Most common side effects were loss of libido in male patients
       (12), nausea (5) and sleeplessness (3). Psychotic reactions, allergy and
       thrombosis occured in one patient, respectively. Adverse reactions lead
       to discontinuation of the drug in 9 (29%) patients. EFFICACY: 21/31
       (67%) patients reported increased appetite and energy levels. No change
       in CD4 cell counts occured. Bodyweight, bodyfat and bodycellmass (BCM)
       were used as measurements for efficacy. Bodyweight increased in 24/31
       (77%) patients, the mean increase was 2.6 kg (STD +/- 2.9) (p < 0.001).
       Bodyfat mass increased by 2.2 kg (STD +/- 2.1) (p < 0.001), whereas BCM
       decreased by 1.3 kg (STD +/- 1.9) (p < 0.05). CONCLUSIONS: In this small
       and retrospective study, MPA treatment of cachexia was safe and showed
       some efficacy in HIV patients. MPA improves appetite and energy levels
       and therefore may improve the quality of life. The effects on the
       bodyweight, however, are limited to the increase in bodyfat, whereas the
       depletion in bodycellmass is not influenced by MPA treatment. Further
       studies to assess the optimal intervention to reverse the loss of BCM in
       cachectic AIDS patients seems to be warranted.
 DE    Cachexia/*DRUG THERAPY/ETIOLOGY  Drug Tolerance  Electric Impedance
       Human  HIV Infections/*COMPLICATIONS/DRUG THERAPY  Male
       Medroxyprogesterone 17-Acetate/ADVERSE EFFECTS/PHARMACOLOGY/
       *THERAPEUTIC USE  Retrospective Studies  Weight Loss/*DRUG EFFECTS
       CLINICAL TRIAL  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).